Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite ...

Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a ...

Amgen (AMGN) stock drops after a phase 3 trial failure for a heart drug from Novartis (NVS) and Ionis Pharma (IONS). BMO ...

Amgen (NASDAQ:AMGN) shares fell 4.7% to $416.88 in premarket trading as investors assessed the implications of a Phase III trial result from Novartis involving an experimental Lp (a)-lowering ...

Amgen raised full-year 2026 revenue and EPS guidance, signaling improved confidence. Find out why AMGN stock is upgraded to ...

Amgen (NASDAQ:AMGN) reported stronger-than-expected fourth-quarter results, posting solid revenue growth and upbeat guidance for 2026, which helped lift its shares slightly in premarket trading on ...

Amgen is getting the ball rolling on a far-reaching new partnership that’s set to boost its profile in its hometown of Greater Los Angeles. The Big Biotech has signed on as the official biotech ...

According to Amgen, DeLLphi-305 is the first Phase 3 study to include a Bispecific T-cell Engager (BiTE) therapy to demonstrate an overall survival benefit in the first-line maintenance setting for ES ...

Adjusted EPS up 5% to $5.15, beating analyst expectations After FDA proposes withdrawing Tavneos approval, Amgen submits label update on liver toxicity Amgen advances MariTide weight-loss drug with ...

Amgen (AMGN) stock popped Wednesday on a solid third-quarter beat as investors focus on what's next for the company's obesity treatment, MariTide. Revenue from cholesterol treatment Repatha surged 40% ...

Amgen reached a $74 million settlement of a lawsuit accusing the biotechnology company of waiting too long to disclose that it might owe the Internal Revenue Service $10.7 billion for underreporting ...